The warehouse is currently able to store controlled, highly potent (HP) and cytotoxic drugs for the company’s clinical supply services business.
Now, after purchasing Aptuit’s clinical trial supplies biz earlier this year , the firm said the move was crucial.
European strategic marketing manager Chris Halling told Outsourcing-Pharma: "This is about Catalent's ability to reliably supply our customers' clinical programs.”
He added the decision is part of Catalent’s strategy to provide a ‘one-stop-shop’ for its clients.
Halling said: “In my view, pharmaceutical and biopharmaceutical companies are coming to rely on fewer strategic partners able to provide global support for multiple trials and the location of Schorndorf is excellent in reaching a wide area within mainland Europe.
“It's also important to many of them that the Schorndorf facility is also able to scale-up production for commercial supply and pack their products too; providing easier transfer for launch."